Company news

Radiopharm Theranostics Limited (ASX:RAD) news

Every Radiopharm Theranostics Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.

Radiopharm Theranostics Limited (ASX:RAD) news

Press releases & updates

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202...

RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

RAD to meet with US FDA to align on RAD 101 Phase 3 Trial

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Austr...

RAD completes A$12.5 M placement and launches A$6 M SPP

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tu...

RAD Achieves Partial Response in Phase 1 Trial of RAD204

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors ...

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

RAD Completes Enrollment in Phase 2b Trial of RAD 101

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

RAD202 Phase 1 HEAT Trial Advances to Dose Level 3

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

RAD Doses First Patient in RAD 402 Phase 1 Clinical Study

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brai...

RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint

Half Year Report and Appendix 4D 31 December 2025

Radiopharm Theranostics : Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)

RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Quarterly Activities/Appendix 4C Cash Flow Report

Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream

Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream

RAD Increases Ownership in Radiopharm Ventures to 87.5%

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metas...

RAD101 interim Phase 2b data - 92% achieve primary endpoint

Radiopharm Theranostics : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

RAD Approval for Phase 1 Therapeutic Trial of RAD 402

Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

RAD Announces 50% Enrollment in Phase 2b Trial of RAD101

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

RAD starts enrollment of 3rd Cohort of Phase 1 177Lu-RAD204

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

RADX: Program and Financial Updates

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on Novembe...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

Prospectus

RAD completes A$35 M Placement and launches A$5 M SPP

Trading Halt

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phas...

Radiopharm received approval for RAD 202 trial acceleration

SPL:Research & Option Agreement with Radiopharm Theranostics

Radiopharm Theranostics : Annual Report for Fiscal Year Ending June 30, 2025 (Form 20-F)

Appendix 4E and Preliminary Final Report

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update